RARE

Ultragenyx Pharmaceutical Inc.
CAPPED RATING

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Ultragenyx Pharmaceutical Inc. (RARE) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Revisions (F). The rating has held at C- for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B
Factor Score 3.2 / 5.0
Growth
B
Factor Score 3.3 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
D
Factor Score 1.4 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 11.2
EV / EBITDA -6.4
Rev Growth YoY 8.1%
Gross Margin -10.7%
Price Return 3M -38.5%
Price Return 12M -52.0%
Catalyst Signal 0.00
Market Cap $1.6B
TTM Revenue $730.0M
Price / Sales 2.2
ROE N/A

Historical Factor Score Progression

Held C- for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B (3.2) B (3.3) C+ (2.6) D (1.4) F (0.0) C- (2.1)
2026-11-07 B (3.2) B (3.3) C+ (2.5) D (1.3) F (0.0) C- (2.1)
2026-10-31 C (2.2) B+ (3.5) C+ (2.6) D (1.3) F (0.0) C- (1.9)
2026-10-24 C (2.3) B (3.5) C+ (2.5) D- (1.1) F (0.0) C- (1.9)
2026-10-17 C (2.4) B (3.5) C+ (2.5) D- (1.0) F (0.0) C- (1.9)
Page 1 of 8
…